Jacobi Capital Management’s Coherus Oncology CHRS Stock Holding History

Jacobi Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200	Closed	-$3K	–	569
2021 Q3	$3K	Hold	200	–	–	﹤0.01%	1261
2021 Q2	$3K	Hold	200	–	–	﹤0.01%	1224
2021 Q1	$3K	Hold	200	–	–	﹤0.01%	1192
2020 Q4	$3K	Hold	200	–	–	﹤0.01%	1095
2020 Q3	$4K	Hold	200	–	–	﹤0.01%	972
2020 Q2	$4K	Hold	200	–	–	﹤0.01%	942
2020 Q1	$3K	Hold	200	–	–	﹤0.01%	895
2019 Q4	$4K	Hold	200	–	–	﹤0.01%	873
2019 Q3	$4K	Hold	200	–	–	﹤0.01%	861
2019 Q2	$4K	Hold	200	–	–	﹤0.01%	860
2019 Q1	$3K	Hold	200	–	–	﹤0.01%	834
2018 Q4	$2K	Buy	+200	New	+$2.31K	﹤0.01%	842

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jacobi Capital Management's CHRS Position: Q4 2021 in Review

Jacobi Capital Management sold out of Coherus Oncology (CHRS) in Q4 2021, closing a stake of 200 shares — an estimated $3K sold.

Jacobi Capital Management first reported a position in CHRS in Q4 2018 and held it in 12 quarters. The position peaked at $4K in Q3 2020. 201 funds tracked by Wall St. Rank hold CHRS as of Q4 2021.

Jacobi Capital Management reported no remaining Coherus Oncology position as of Q4 2021 after selling out during the quarter.
Jacobi Capital Management sold 200 Coherus Oncology shares in Q4 2021, an estimated $3K.
Jacobi Capital Management first reported a position in Coherus Oncology in Q4 2018 and held it in 12 quarters.
Jacobi Capital Management's Coherus Oncology position peaked at $4K in Q3 2020.
201 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.